Alaunos Therapeutics, Inc.

Alaunos Therapeutics announced new preclinical statistical analysis for its investigational metabolic candidate, ALN1003. In a 48-day diet-induced obesity mouse study, ALN1003-treated animals exhibited lower liver weight after adjusting for body fat percentage, a finding directionally consistent with previous data on liver markers, histology, HOMA-IR, and adipose endocrine biomarkers. The company emphasized that these are non-GLP preclinical findings and may not translate to human efficacy or safety, urging appropriate caution.

Alaunos Therapeutics announced new preclinical statistical analysis for its investigational oral metabolic candidate, ALN1003. The analysis showed ALN1003-treated animals had lower liver weight after adjustment for body fat percentage, consistent with previously disclosed positive findings related to liver injury, NAFLD Activity Scores, insulin resistance, and adipose endocrine signaling. While these non-GLP findings support further evaluation, the company also disclosed a cash position of $0.354 million as of March 31, 2026, and plans to seek additional financing.

Alaunos Therapeutics announced an integrated preclinical readout for ALN1003, its investigational oral candidate for obesity and metabolic disorders. The findings from two non-GLP diet-induced obesity mouse studies showed broad metabolic improvements, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and better liver health. While these early results are positive, the company reported a cash position of approximately $0.354 million as of March 31, 2026, with a cash runway extending only into the second quarter of 2026, indicating a need for additional financing.

Alaunos Therapeutics reported positive integrated preclinical results for ALN1003, its investigational oral candidate for obesity and metabolic disorders. Studies in diet-induced obese mice demonstrated consistent improvements across key metabolic disease drivers, including significant reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and better liver health. The company plans further preclinical studies, formulation optimization, and manufacturing activities, but noted its cash position of $0.354 million as of March 31, 2026, with a runway into Q2 2026, necessitating additional financing.

Alaunos Therapeutics announced updated preclinical data for ALN1003, its investigational oral metabolic therapeutic candidate for obesity and related metabolic disorders. The findings from non-GLP diet-induced obesity mouse studies showed effects on insulin-resistance-related biomarkers, adipose endocrine signaling, and qualitative liver histology consistent with lower hepatic steatosis. While these early preclinical results are encouraging, the company emphasized that ALN1003 has not been evaluated in human clinical trials. Additionally, Alaunos reported cash and cash equivalents of $0.354 million as of March 31, 2026, with a cash runway extending only into the second quarter of 2026, necessitating additional financing.

Alaunos Therapeutics reported a net loss of $1.0 million for Q1 2026, with cash and cash equivalents of $0.35 million as of March 31, 2026, expected to fund operations only into Q2 2026. The company faces substantial doubt about its ability to continue as a going concern and received a Nasdaq notice for non-compliance with the minimum stockholders' equity requirement, risking delisting. The company is focused on its early preclinical Obesity and Metabolic Disorders Program.

Alaunos Therapeutics, Inc. (TCRT) filed an amended 10-K to include Part III information, previously omitted, covering corporate governance and executive compensation. The amendment details the appointment of Holger Weis as CEO in July 2025 with an annual base salary of $275,000 and an option to purchase 130,000 shares. It also outlines changes to the Board of Directors, including the appointment of Michael A. Jerman and the resignations of Dale Curtis Hogue and Dr. Robert Hofmeister, along with executive compensation for 2025 and 2024.

Alaunos Therapeutics, Inc. received a notice from Nasdaq on April 9, 2026, indicating non-compliance with Listing Rule 5550(b)(1). The company's stockholders' equity of $2,153,000, as reported in its 2025 Annual Report, falls below the required minimum of $2,500,000 for continued listing on the Nasdaq Capital Market. Additionally, the company does not meet alternative listing standards based on market value or net income. Alaunos Therapeutics plans to submit a compliance plan within 45 days, by May 26, 2026, to address the deficiency.